Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets
Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.


Pharmaceutical Technology



Table V: Radial and axial swelling of tablets in distilled water.
The study of dimensional changes in the tablets was carried out for 5 h in distilled water (see Table V). As the proportion of dried mucilage increased, the radial and axial swelling of the tablet increased. When the drug–mucilage ratio was at its lowest (1:0.5), the swelling of the tablet was at its lowest. As the ratio increased, the radial and axial swelling increased proportionally. There was more swelling of the tablet in the axial direction compared with the radial direction.


FIGURE1: C.K.Pithawala Institute of Pharmaceutical Science and Research
The dried mucilage was evaluated as a matrix-forming material for oral sustained-released tablets using diclofenac sodium as a model drug. Matrix tablets, each containing 100 mg of diclofenac sodium, were prepared using dried mucilage in various drug–mucilage ratios (1:0.5, 1:1, 1:1.5, and 1:2). An ideal modified-release dosage form should release a loading dose (20–25%) in the first hour. Later, the remaining drug should be released at a constant rate over an extended period. An ideal release pattern was calculated according to these criteria. The in vitro dissolution profiles are shown in Figure 1. Batches A1 and A2, at lower the ratios (1:0.5 and 1:1), released 35.45 and 30.70% of the drug in the first hour, and the remaining drug was released within 6 h. This result occurred probably because insufficient polymer was in the formulation. In batch A4 , where the drug-mucilage ratio was 1:2, 23.25% of the drug was released in the first hour, and the remaining drug was released during 8 h. The rate of release was faster in batch A1 and slower in batch A4. This result showed that as the proportion of mucilage increased, the overall time of release of the drug from the matrix tablet increased. Drug release from swellable and erodible hydrophilic matrices can be attributed to polymer dissolution, drug diffusion through gel layer, or a combination of both.

Conclusion

From this preliminary study, the mucilage extracted from Aloe barbadensis Miller appears suitable for use as a pharmaceutical excipient in the formulation and manufacture of sustained-release matrix tablets because of its good swelling, good flow, and suitability for direct-compression formulations. From the dissolution study, it was concluded that the dried mucilage can be used as an excipient for sustained-release, modified-release, and fast-release tablets with suitable modifications.

References

1. L.M. Prashant and W.J. Elliot, "Drug Delivery Systems for Treatment of Systemic Hypertension," Clin. Pharmkinet. 42 (11), 931–940 (2003).

2. A. Boza et al.,"Evaluation of Eudrajit RS-PO and Ethocel 100 Matrices for Controlled Released of Lobenzarit Disodium," Drug Dev. Ind. Pharm. 25 (2), 229–233 (1999).

3. S.A. Bravo, M.C. Lamas, and C.J. Salomon, "Swellable Matrices for the Controlled Release of Diclofenac Sodium: Formulation and In-vitro Studies," Pharm. Dev. Technol. 9 (1), 75–83 (2004).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here